Rapid vigilance and episodic memory decrements in COVID-19 survivors.

COVID-19 cognitive deficits long-COVID memory sustained attention

Journal

Brain communications
ISSN: 2632-1297
Titre abrégé: Brain Commun
Pays: England
ID NLM: 101755125

Informations de publication

Date de publication:
2022
Historique:
received: 06 07 2021
revised: 08 10 2021
accepted: 20 12 2021
entrez: 7 2 2022
pubmed: 8 2 2022
medline: 8 2 2022
Statut: epublish

Résumé

Recent studies indicate that COVID-19 infection can lead to serious neurological consequences in a small percentage of individuals. However, in the months following acute illness, many more suffer from fatigue, low motivation, disturbed mood, poor sleep and cognitive symptoms, colloquially referred to as 'brain fog'. But what about individuals who had asymptomatic to moderate COVID-19 and reported no concerns after recovering from COVID-19? Here, we examined a wide range of cognitive functions critical for daily life (including sustained attention, memory, motor control, planning, semantic reasoning, mental rotation and spatial-visual attention) in people who had previously suffered from COVID-19 but were not significantly different from a control group on self-reported fatigue, forgetfulness, sleep abnormality, motivation, depression, anxiety and personality profile. Reassuringly, COVID-19 survivors performed well in most abilities tested, including working memory, executive function, planning and mental rotation. However, they displayed significantly worse episodic memory (up to 6 months post-infection) and greater decline in vigilance with time on task (for up to 9 months). Overall, the results show that specific chronic cognitive changes following COVID-19 are evident on objective testing even amongst those who do not report a greater symptom burden. Importantly, in the sample tested here, these were not significantly different from normal after 6-9 months, demonstrating evidence of recovery over time.

Identifiants

pubmed: 35128398
doi: 10.1093/braincomms/fcab295
pii: fcab295
pmc: PMC8807287
doi:

Types de publication

Journal Article

Langues

eng

Pagination

fcab295

Subventions

Organisme : Medical Research Council
ID : MR/V036858/1
Pays : United Kingdom

Informations de copyright

© The Author(s) (2022). Published by Oxford University Press on behalf of the Guarantors of Brain.

Références

JAMA. 2020 Aug 25;324(8):782-793
pubmed: 32648899
Ann Clin Transl Neurol. 2021 May;8(5):1073-1085
pubmed: 33755344
Science. 2021 May 28;372(6545):
pubmed: 33906968
J Pers Assess. 2009 Mar;91(2):166-74
pubmed: 19205937
N Engl J Med. 2020 Jun 4;382(23):2268-2270
pubmed: 32294339
J Neurol Neurosurg Psychiatry. 2021 May;92(5):567-568
pubmed: 33219042
J Psychiatr Res. 2020 Oct;129:98-102
pubmed: 32912598
Neuropsychopharmacology. 2021 Dec;46(13):2235-2240
pubmed: 33589778
Front Psychiatry. 2021 Feb 10;11:621773
pubmed: 33643083
JAMA Neurol. 2020 Jun 1;77(6):683-690
pubmed: 32275288
Behav Res Methods. 2019 Feb;51(1):195-203
pubmed: 30734206
Behav Res Methods. 2011 Jun;43(2):548-67
pubmed: 21424189
Lancet Psychiatry. 2021 May;8(5):416-427
pubmed: 33836148
PLoS One. 2017 Jan 11;12(1):e0169938
pubmed: 28076387
Nat Med. 2021 Sep;27(9):1607-1613
pubmed: 34163090
Br J Clin Psychol. 1982 Feb;21(1):1-16
pubmed: 7126941
Nat Rev Neurosci. 2008 Aug;9(8):613-25
pubmed: 18641668
Health Qual Life Outcomes. 2010 Feb 12;8:22
pubmed: 20152031
EClinicalMedicine. 2021 Sep;39:101044
pubmed: 34316551
J Nucl Med. 2021 Jul 1;62(7):910-915
pubmed: 33789937
Lancet. 2021 Jan 16;397(10270):220-232
pubmed: 33428867
Brain Cogn. 1998 Dec;38(3):317-38
pubmed: 9841789
Lancet Psychiatry. 2020 Oct;7(10):875-882
pubmed: 32593341
Acta Psychiatr Scand. 1983 Jun;67(6):361-70
pubmed: 6880820
Nat Rev Neurosci. 2010 Sep;11(9):651-9
pubmed: 20725096
Brain Sci. 2021 Feb 13;11(2):
pubmed: 33668456
Brain. 2021 May 7;144(4):1263-1276
pubmed: 33822001
Philos Trans R Soc Lond B Biol Sci. 1982 Jun 25;298(1089):199-209
pubmed: 6125971
JAMA. 2020 Aug 11;324(6):603-605
pubmed: 32644129
EClinicalMedicine. 2021 Jan 07;31:100683
pubmed: 33490928
Brain Commun. 2020 Nov 23;2(2):fcaa205
pubmed: 33376990
Lancet Psychiatry. 2020 Jul;7(7):611-627
pubmed: 32437679
Eur Neuropsychopharmacol. 2021 May;46:39-48
pubmed: 33823427
N Engl J Med. 2021 Feb 4;384(5):481-483
pubmed: 33378608
Evol Hum Behav. 2000 May 1;21(3):201-213
pubmed: 10828558
Psychol Bull. 2013 Jul;139(4):870-900
pubmed: 23163491
Science. 1983 Apr 15;220(4594):327-9
pubmed: 6836276
Handb Clin Neurol. 2018;151:525-553
pubmed: 29519478
J Neurovirol. 2021 Feb;27(1):191-195
pubmed: 33528824
Nat Med. 2021 Apr;27(4):601-615
pubmed: 33753937

Auteurs

Sijia Zhao (S)

Department of Experimental Psychology, University of Oxford, Oxford OX1 3PH, UK.

Kengo Shibata (K)

Nuffield Department of Clinical Neurosciences, University of Oxford, Oxford OX3 9DU, UK.

Peter J Hellyer (PJ)

Department of Brain Sciences, Imperial College London, 926, Sir Michael Uren Hub, 86 Wood Lane, London W12 0BZ, UK.

William Trender (W)

Department of Brain Sciences, Imperial College London, 926, Sir Michael Uren Hub, 86 Wood Lane, London W12 0BZ, UK.

Sanjay Manohar (S)

Department of Experimental Psychology, University of Oxford, Oxford OX1 3PH, UK.

Adam Hampshire (A)

Department of Brain Sciences, Imperial College London, 926, Sir Michael Uren Hub, 86 Wood Lane, London W12 0BZ, UK.

Masud Husain (M)

Department of Experimental Psychology, University of Oxford, Oxford OX1 3PH, UK.

Classifications MeSH